“…Notably, TCAs and SSRIs have low-affinity interactions with a diverse group of membrane proteins (Rammes and Rupprecht, 2007; Bianchi, 2008; see also Table S1), which may provide additional mechanisms for altering neural chemistry and circuitry (Duman et al, 2016). The mechanisms underlying this polypharmacology remain unclear, but integral membrane proteins have two things in common: they are membrane spanning, and their activity can be modulated by changes in lipid bilayer properties (curvature, thickness, and elasticity) that can be induced by the addition of amphiphiles, including many biologically active molecules (e.g., a variety of toxins; Suchyna et al, 2004; Dockendorff et al, 2018), currently used or discontinued drugs (Rusinova et al, 2011, 2015), and phytochemicals (Ingólfsson et al, 2014; see also Lundbæk et al, 2010b, Table 3).…”